만성폐쇄성폐질환에서 상피중간엽이행 조절을 통한 Celecoxib의 폐 손상 개선효과

국문 초록 (Abstract)

본 연구는 만성폐쇄성폐질환(COPD)의 동물 모델을 이용하여 Celecoxib의 폐 손상 개선효과를 연구하였다. COPD는 LPS와 담배연기추출물(CSE)로 유도하여 in vitro와 in vivo에서 병행 연구하였다. In vitro는 인간 섬유아 세포(MRC5)에서 MTT assay, real-time PCR를 하였고 in vivo는 mRNA 발현, 기관지폐포세척액(BALF), collagen content, 단백질 발현을 확인하였다. 실험을 통해 Celecoxib는 BALF에서 염증세포 수의 감소와 사이토 카인, soluble protein의 축적을 감소시켰고 동물모델에서는 체중과 폐 무게를 감소시켰으며, 폐 콜라젠 축적도 개 선하였다. 또 웨스턴 블로팅과 real-time PCR을 통해 EMT 표지자의 감소를 확인하였다. 결과적으로 Celecoxib는 EMT를 조절하여 LPS+CSE로 유도된 COPD의 폐 손상에서 개선제로 작용할 수 있을 것으로 사료된다.

다국어 초록 (Multilingual Abstract)

This study confirmed the effects of improving lung damage of celecoxib using an animal model of chronic obstructive pulmonary disease(COPD). It was induced in models LPS + CSE and performed in vitro and in vivo. MTT assay and real-time PCR were performed in MRC5 cells as in vitro, and mRNA expression, BALF, collagen content, and protein expression were confirmed as in vivo. Celecoxib reduced the number of inflammatory cells, cytokine and soluble protein accumulation in BALF, decreased body weight and lung weight in animal models, and improved lung collagen deposition. In addition, the reduction of EMT markers was confirmed through Western blotting and real-time PCR. Consequently, celecoxib is thought to improve lung damage of COPD induced to LPS+CSE by regulating EMT.

목차 (Table of Contents)

• 요약
• Abstract
• 1. 서론
• 2. 재료 및 방법
• 2.1 재료
• 2.2 세포 배양
• 2.3 동물 및 COPD 모델 제작
• 2.4 세포 생존률(MTT assay) 측정
• 2.5 체중 및 폐 중량 측정
• 2.6 Real-time PCR 측정
• 2.7 웨스턴 블로팅(Western blotting)
• 2.8 면역세포화학검사(Immunocytochemistry)
• 2.9 기관지폐포세척액(Bronchoalveolar lavage fluid, BALF)
• 2.10 사이토카인(Cytokine) 측정
• 2.11 Soluble collagen 측정
• 2.12 통계분석
• 3. 연구 결과
• 3.1 Celecoxib가 세포 생존율에 미치는 영향
• 3.2 LPS와 CSE에 의해 유도된 세포의 COPD모델에서 Celecoxib의 EMT 억제 효과
• 3.3 동물모델에서 Celecoxib가 동물의 몸무게 및 폐의 무게에 미치는 영향
• 3.4 LPS와 CSE에 의해 유도된 동물의 COPD 모델에서 Celecoxib의 EMT 억제 효과
• 3.5 LPS와 CSE에 의해 유도된 COPD 동물모델에서 Celecoxib의 soluble- collagen 억제 효과
• 3.6 LPS와 CSE에 의해 유도된 동물의 COPD모델에서 Celecoxib의 폐 염증 억제 효과
• 4. 고찰
• 5. 결론
• REFERENCES

참고문헌 (Reference)

1 A. Soltani, "Vessel-associated transforming growth factor-beta1 (TGF-β1) is increased in the bronchial reticular basement membrane in COPD and normal smokers" 7 (7): e39736-, 2012

2 M. Xie, "Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017" 21 (21): 49-, 2020

3 Q. Wang, "The role of uPAR in epithelialmesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease" 14 : 67-, 2013

4 P Venkatesan, "The potential of celecoxibloaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer" 32 : 3794-3806, 2011

5 J. C. Hogg, "The pathology of chronic obstructive pulmonary disease" 4 (4): 435-459, 2009

6 J. C. Hogg, "The nature of small-airway obstruction in chronic obstructive pulmonary disease" 350 (350): 2645-2653, 2004

7 P. J. Barnes, "The cytokine network in chronic obstructive pulmonary disease" 41 (41): 631-638, 2009

8 M. Javier, "Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition" 67 (67): 147-156, 2012

9 M. Rincon, "Role of IL-6 in asthma and other inflammatory pulmonary diseases" 8 (8): 1281-1290, 2012

10 M. Rincon, "Role of IL-6 in asthma and other inflammatory pulmonary diseases" 8 (8): 1281-1290, 2012

11 J. X. Jiang, "Rac1 signaling regulates cigarette smoke-induced inflammation in the lung via the Erk1/2 MAPK and STAT3 pathways" 1863 (1863): 1778-1788, 2017

12 R. Chatterjee, "ROS and oncogenesis with special reference to EMT and stemness" 99 : 151073-, 2020

13 K. H. Yoo, "Prevalence of chronic obstructive pulmonary disease in Korea : the fourth Korean National Health and Nutrition Examination Survey, 2008" 16 (16): 659-665, 2011

14 G. G. Brusselle, "New insights into the immunology of chronic obstructive pulmonary disease" 378 (378): 1015-1026, 2011

15 A. Butler, "Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease" 15 (15): 392-404, 2018

16 I. Tsiligianni, "Morning and night symptoms in primary care COPD patients : a cross-sectional and longitudinal study" 26 : 16040-, 2016

17 P. J. Barnes, "Immunology of asthma and chronic obstructive pulmonary disease" 8 (8): 183-192, 2008

18 N. Kaosia, "Epithelialmesenchymal transition as a fundamental underlying pathogenic process in COPD airways : fibrosis, remodeling and cancer" 8 (8): 547-559, 2014

19 D. Bartis, "Epithelial-mesenchymal transition in lung development and disease : does it exist and is it important" 69 : 760-765, 2014

20 J. Milara, "Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke" 68 : 410-420, 2013

21 D. Chakroborty, "Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells" 108 : 20730-20735, 2011

22 V. M. Keatings, "Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma" 153 (153): 530-534, 1996

23 D. G. Menter, "Cyclooxygenase-2 and cancer treatment : understanding the risk should be worth the reward" 16 : 1384-1390, 2010

24 T. H. Chu, "Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN" 5 : 1475-1490, 2014